5 Year Sale Growth of Novo Nordisk A/S (NYSE:NVO) is reported at 12.17


Quarterly Sales and EPS Roundup:

Novo Nordisk A/S (NYSE:NVO) reported sales (ttm) of 15.76 Billion, whereas, 1 number of analysts estimated the mean sale of 4220.18 million. The analysts estimated sales for the higher end at 4220.18 million and lower end at 4220.18 million while the year ago reported sale was 0 million.

2 number of analysts have estimated the sales of the company for the quarter, analysts estimated mean sale target of 16209.8 million while high and low sale targets are estimated at 16350.5 million and 16069.1 million respectively.

Novo Nordisk A/S (NYSE:NVO) reported earning per shares for the quarter ending Oct 28 BMO at 0.58, whereas, 1 number of analysts estimated the mean EPS at 0.52. The analysts estimated EPS for the higher end at 0.52 and lower end at 0.52 while the year ago reported earnings per share was 0.

The company has mean EPS estimate of 2.24 reported by 2 number of analyst for the quarter. The analysts estimated mean EPS at 2.24 while the high and low EPS estimate stand at 2.27 and 2.21 respectively. In contrast to the year ago quarter EPS was at 2.27.

Valuation Ratios of Novo Nordisk A/S (NYSE:NVO) versus the Industry and Sector:

Let’s have a look at some of the important valuation ratios of the Novo Nordisk A/S (NYSE:NVO). These ratios are important while doing valuation of the company or the shares of the company.

Novo Nordisk A/S (NYSE:NVO) currently has P/E (Price to Earnings) ratio of 15.31 while the company’s industry has 29.13 P/E and the sector P/E is 29.87. Similarly, the company’s last 5 years high P/E ratio is 29.51 and low P/E is 21.45, whereas, the industry’s and sector’s  high P/E for the past year is 41.74 and 43.94 respectively and low P/E ratio for the last 5 years is 18.34 for the industry and 19.95 for the Sector.

Beta is also an important valuation ratio for analyzing the stock of the company, 28 has Beta of 0.79 while its industry and Sector’s beta remains at 0.84 and 0.83 respectively.

Price to Sale ratio of 28 stands at 4.1 while Price to Book Ratio stands at 14.19. Its Price to Cash Flow ratio shows the value of 11.24, whereas, the industry and sector ratio of Price to Cash Flow ticked at 22.73 and 22.64 respectively.

5 Year Growth Rate Analysis:

Growth rates are very important while analyzing the long term growth and valuation of a certain company.

5 year sales growth rate is an important factor for valuation analysis, the 5 year sales growth of Novo Nordisk A/S (NYSE:NVO) stands at 12.17 while the industry’s and the sector’s growth for next 5 years ticked at 10.56 and 10.88 respectively. The company’s 5 year Earnings per share growth and Capital Spending growth remains at 22.41 and 10.45.

Novo Nordisk A/S (NYSE:NVO) Trading Statistics:

The company surged 2.69% and closed its last trading session at $32.72. The market capitalization of the company is at $67.52 Billion. The stock touched 52-week High of $59 on Dec 30, 2015 and 52-week Low of $30.89 on Nov 23, 2016. The stock currently has Weekly Volatility of 1.41% and Monthly Volatility of 1.57%. The Beta for the company stands at 0.77 and its Average True Range (ATR) shows a value of 0.83.